The post grants GLP-1 drugs may help people with real health needs but warns of a negative effect, without saying what it is in the preview.
Recap by typeshit. Post by Facebook on Facebook.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Online sellers pitch peptides for weight loss, anti-aging and muscle gain, and Gavin Coote's full story looks at the risks of products nobody regulates.
Tirzepatide alone reached 14.8% in the same trial. The catch: up to 27% of people on the combination quit over side effects, per the Motley Fool writeup.
Healio
Researchers compared 22,694 first-time semaglutide users with 229,640 controls. Lead author Mille Dybdal Bager says the link shouldn't be read as cause and effect.
Loading…